MedTrace Logo

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

NCT03131154 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2025-02-10

Study results available
· View outcomes & findings →

Summary

A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.

Conditions

  • Non-infectious Anterior Uveitis

Interventions

DRUG

ADX-102 Ophthalmic Solution (0.5%)

ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.

DRUG

Vehicle of ADX-102 Ophthalmic Solution

Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.

Sponsors & Collaborators

  • Aldeyra Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2019-04-19
Completion
2019-04-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131154 on ClinicalTrials.gov